The pharmaceutical industry’s move toward increased U.S.-based manufacturing is changing the landscape of career ...

As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

The pharmaceutical industry stands at a critical juncture. To navigate the complexities of sophisticated drug development and manufacturing, a fundamental shift toward AI-powered technologies is ...

The Greensboro facility features cleanroom space, automated production lines, and full laboratory capabilities for testing and metrology.

Why tariffs could fuel a new era of domestic pharma manufacturing With tariffs threatening the sector’s low-cost sourcing playbook, pharma is being forced to rethink supply chain resilience from the ...

A number of other drugmakers have rolled out similar plans to ramp up U.S. manufacturing in recent days, in the face of ...

AstraZeneca (AZN) said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have announced more than $200 billion combined in investments in the coming ...

Lilly's new plant in North Carolina, which is the company's second in the state, uses a mix of automation and robotics to crank out injectable drugs.

Discover how pharmaceutical companies are utilising digital tools such as AI to enhance drug discovery and clinical development processes. Stay ahead of the curve with the latest advancements in R&D.

Vetter Pharma broke ground this week on a new $285 million pharmaceutical facility.

President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to ...